Function of TCF-1 in antagonizing malignancy

NIH RePORTER · NIH · R21 · $220,000 · view on reporter.nih.gov ↗

Abstract

The human immune system is naturally capable of killing cancer cells. But mutations and other abnormalities handicap or neutralize it, making the immune system insufficient and ineffective. Currently there is a lot of investment being made to study how to stimulate the immune system to kill cancer cells. However, there is evidence that in certain circumstances boosting the immune system actually encourages cancer cell growth. We’re trying to understand how this phenomenon works. Particularly, under the circumstances when a TCF-1 gene mutation is involved — the immune system, when stimulated, actually promotes the growth of lymphoma. We expect to learn how TCF-1 gene regulates the immune responses to affect the lymphoma development.

Key facts

NIH application ID
10281056
Project number
1R21AI163256-01
Recipient
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
Principal Investigator
Zuoming Sun
Activity code
R21
Funding institute
NIH
Fiscal year
2021
Award amount
$220,000
Award type
1
Project period
2021-08-01 → 2023-07-31